Ftse Mib
34.492,41
0,13%
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
NASDAQ
16.735,02
-0,01%
Bitcoin
67.731,41
0,01%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ GlycoMimetics Inc (GLYC) GlycoMimetics Inc (GLYC) Notizie

GLYC

GlycoMimetics (GLYC)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:GLYC
DataOraFonteTitoloSimboloCompagnia
29/05/202422:01Business WireGlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024NASDAQ:GLYCGlycoMimetics Inc
09/05/202422:31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GLYCGlycoMimetics Inc
06/05/202422:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLYCGlycoMimetics Inc
06/05/202412:00Business WireGlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)NASDAQ:GLYCGlycoMimetics Inc
25/04/202413:00Business WireGlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024NASDAQ:GLYCGlycoMimetics Inc
27/03/202412:00Business WireGlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023NASDAQ:GLYCGlycoMimetics Inc
13/03/202412:00Business WireGlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024NASDAQ:GLYCGlycoMimetics Inc
26/02/202413:00Business WireGlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care ConferenceNASDAQ:GLYCGlycoMimetics Inc
12/02/202413:00Business WireGlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:GLYCGlycoMimetics Inc
17/01/202422:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLYCGlycoMimetics Inc
04/01/202413:00Business WireGlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687NASDAQ:GLYCGlycoMimetics Inc
03/01/202413:00GlobeNewswire Inc.Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid LeukemiaNASDAQ:GLYCGlycoMimetics Inc
10/12/202318:00Business WireGlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid LeukemiaNASDAQ:GLYCGlycoMimetics Inc
09/11/202313:00Business WireGlycoMimetics to Participate in Upcoming Jefferies London Healthcare ConferenceNASDAQ:GLYCGlycoMimetics Inc
03/11/202312:00Business WireGlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023NASDAQ:GLYCGlycoMimetics Inc
23/10/202314:30PR Newswire (US)Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory BoardNASDAQ:GLYCGlycoMimetics Inc
20/10/202313:00Business WireGlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023NASDAQ:GLYCGlycoMimetics Inc
06/09/202313:00Business WireGlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687NASDAQ:GLYCGlycoMimetics Inc
05/09/202313:00Business WireGlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:GLYCGlycoMimetics Inc
17/08/202313:00Business WireGlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:GLYCGlycoMimetics Inc
02/08/202313:00Business WireGlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023NASDAQ:GLYCGlycoMimetics Inc
19/07/202313:00Business WireGlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023NASDAQ:GLYCGlycoMimetics Inc
26/06/202314:00Business WireGlycoMimetics Announces Its Addition to the Russell Microcap® Index  NASDAQ:GLYCGlycoMimetics Inc
15/06/202314:00Business WireGlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid LeukemiaNASDAQ:GLYCGlycoMimetics Inc
02/06/202322:11Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GLYCGlycoMimetics Inc
31/05/202313:00Business WireGlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare ConferenceNASDAQ:GLYCGlycoMimetics Inc
22/05/202322:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:GLYCGlycoMimetics Inc
17/05/202317:12Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:GLYCGlycoMimetics Inc
03/05/202314:35Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:GLYCGlycoMimetics Inc
03/05/202313:00Business WireGlycoMimetics Reports Highlights and Financial Results for First Quarter 2023NASDAQ:GLYCGlycoMimetics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:GLYC

La tua Cronologia

NASDAQ
ANGL
VanEck Fallen Angel High...
NASDAQ
DBGI
Digital Brands
LSE
HFD
Halfords
BIT
P18VJ2
BNP Paribas Issuance
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network